
Please try another search
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Dong-Ho Lee | 71 | - | Independent Non-Executive Director |
Jong-Soo Woo | 58 | 2017 | Executive Director |
Lim Chong-Yoon | 53 | - | President of Business Development & Executive Director |
Jong-Hoon Lim | 48 | - | Executive Director & Management Planning /CIO |
Dong-Cheol Suh | 69 | - | Independent Non-Executive Director |
Jae-Hyun Park | 57 | 2023 | CEO & Director |
Dong Ho Lee | - | - | Independent Non-Executive Director |
Sung-Hoon Kim | 67 | - | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review